Drug Information

Drug General Information
Drug ID
D03ISJ
Former ID
DNC002387
Drug Name
BMS-863233
Drug Type
Small molecular drug
Indication Hematological malignancies [ICD9: 200-209; ICD10:C81-C86] Phase 1/2 [522575], [542978]
Company
Bristol Myers Squibb
Structure
Download
2D MOL

3D MOL
Formula
C14H12ClN3O2
InChI
InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m0/s1
InChIKey
JJWLXRKVUJDJKG-VIFPVBQESA-N
PubChem Compound ID
57899889
PubChem Substance ID
137906524, 152146473, 160694662, 160862797, 172113662, 198952036, 210275205, 210280844, 228024987, 245567473, 249565793
Target and Pathway
Target(s) CDC7 protein kinase Target Info Modulator [531895]
NetPath Pathway TGF_beta_Receptor Signaling Pathway
References
Ref 522575ClinicalTrials.gov (NCT00838890) A Study of BMS-863233 in Patients With Hematologic Cancer. U.S. National Institutes of Health.
Ref 542978(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8113).
Ref 531895Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.